- Adventia Pharma believes that the first phase of the project has been developed as planned from the technical and budgetary point of view

- The research group at the Hospital de La Paz has made progress in reviewing the nutritional status of oncological patients described in the literature worldwide

- Work has already begun on conditioning the raw material by microencapsulation to reduce its organoleptic impact

The R & D ALISENOC project has "satisfactorily" overcome the first of the three technical-economic milestones included in its work plan. This has been stated by the management team of Adventia Pharma, which leads this initiative whose objective is to develop a diet based on nutrients and bioactive compounds for the nutritional treatment of cancer patients, thus improving their quality of life.

During this first phase of execution of the project, the research group on Nutrition and Functional Foods (NUTRinvest), from the Madrid University Hospital of La Paz, has advanced in the review of the nutritional status of oncological patients described in literature worldwide. To this end, we have consulted different pages of institutions and organizations related to nutrition and nutritional support, as well as the study pathology: cancer. In this analysis, the existing documentation about nutrients or bioactive compounds of foods that show scientific evidence about their benefits that enhance the anti-tumor treatments received by cancer patients has been verified.

This bibliographical review has been very useful to find a great variety of nutrients and beneficial compounds for the nutritional health of these patients. However, before approving its introduction in the supplement to be developed by ALISENOC, the legal recognition of each of them has been verified by Adventia and the legal team of the AINIA technology center, and, consequently, all those that were lacking have been discarded. of still result at the legislative level.

In parallel, NUTRinvest has also developed a table of oral nutritional supplementation products with specific indication in the prospectus for "oncological patient" that are currently marketed in Spain. This table has served as a basis to be able to contrast the information of these products with the nutritional profile proposal that will be designed ALISENOC.

From Adventia Pharma, in collaboration with AINIA, have begun to develop the trials of conditioning of raw materials, focusing on reducing the organoleptic impact of these. Based on the technical and bibliographic information collected and based on the previous experience of AINIA, microencapsulation technologies have been chosen. In addition, thanks to this literature review, several coating materials of this microencapsulation have also been selected, based on their potential interest in terms of their contrasted reduction in organoleptic impact.

On the other hand, the preparation of liquid diets at the pilot level has begun in order to evaluate and adjust the formulas to the physical-chemical quality criteria of the product after processing. Thus, the influence of the operations of the mixing and homogenization process on the physicochemical characteristics of the complete liquid diets are also evaluated on a laboratory scale.

ALISENOC was launched in September 2017 with an estimated duration of three years. Adventia Pharma leads this project that has a budget of over 400,000 euros, co-financed by the CDTI with FEDER funds from the European Union.